2,4-Dichloropyrimidine CAS:3934-20-1

2,4-Dichloropyrimidine

Chemical Name:2,4-Dichloropyrimidine
CAS.NO:3934-20-1
Synonyms:2,4-dichloro-pyrimidine
2-Chloropyrimidin-4-yl chloride
2,4-Dichlorpyrimidin
Pyrimidine, 2,4-dichloro-
Molecular Formula:C4H2Cl2N2
Molecular Weight:148.97800
 
Physical and Chemical Properties:
Density:1.493
Melting point:60-61ºC
Boiling point:101ºC
Flash point:104.3±5.4ºC
Index of Refraction:1.559
 
Specification:
Appearance:Pale yellow or offwhite crystalline
Assay(HPLC):≥98.0%
Moisture:≤0.2%
Residue on ignition:≤0.3%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of minoxidil.



We are professional 2,4-dichloro-pyrimidine manufacturer and 2,4-Dichloropyrimidine supplier in China, We offer quality 2,4-Dichlorpyrimidin you can fully trust, also we have India factory and producer of 2,4-Dichloropyrimidine,Pls send inquiry of 2-Chloropyrimidin-4-yl chloride CAS:3934-20-1 to info@nbinno.com if you have any interests, thank you!


Related News: The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.Nonafluorohexyltrichlorosilane CAS:78560-47-1 The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.2,4,6-Tribromophenyl isothiocyanate CAS:22134-11-8 At the same time, through years of imitation and advanced technology learning, more and more domestic companies have participated in the field of highly original and characteristic APIs.(Bromomethyl)cyclopropane Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).